Michael Chi, the Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently conducted stock transactions as reported in a Form 4 filing with the Securities and Exchange Commission. On January 21, 2025, Chi exercised options to acquire 306 shares of Class A Common Stock at a price of $13.90 per share. Following this, he sold the same number of shares at a price of $28.68 each, resulting in a total sale value of $8,776.
These transactions were executed under a Rule 10b5-1 trading plan adopted on March 1, 2024. After the completion of these trades, Chi holds 193,601 shares directly.
In other recent news, Hims & Hers Health has been the focus of several significant developments. The company reported a robust 77% year-over-year increase in Q3 sales, surpassing $400 million, and an adjusted EBITDA over $50 million. Revenue projections for Q4 2024 range between $465 million and $470 million, indicating a significant year-over-year increase. BofA Securities maintained an Underperform rating on the company's shares, citing concerns about the future of the company's compounded GLP-1 products due to aggressive defense tactics by pharmaceutical manufacturers. Meanwhile, BTIG initiated coverage with a Buy rating and a price target of $35.00, highlighting the company's innovative business model and high demand for its offerings. Needham & Company positioned Hims & Hers as their top pick for 2025, citing the company's diverse growth avenues. Lastly, the company announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.